09/03/2026 Pfizer announced Phase 2 results of tilrekimig in AD Pfizer announced Phase 2 results of tilrekimig in AD ( Ref ) Pfizer announced positive topline results from its Phase 2 study that evaluated tilrekimig (PF-07275315; trispecific antibody targets Il-4, IL-13 and TSLP) for the treatment of adult patients with moderate to severe atopic dermatitis (AD) The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of particip

06/03/2026 The US FDA approved deucravacitinib for the treatment of patients with active PsA Aisa Pharma announced the results from its Phase 2 trial of AISA-021 in patients with SSc RP The US FDA approved deucravacitinib for the treatment of patients with active PsA ( Ref ) BMS announced that the US FDA had approved Sotyktu® (deucravacitinib; TYK2 inhibitor) for the treatment of adult patients with active psoriatic arthritis (PsA) The approval was based on positive results f

24/02/2026 Abcuro announced topline results from its Phase 2/3 study of ulviprubart in patients with inclusion body myositis J&J submitted sBLA to the US FDA for approval of IMAAVY® for warm autoimmune hemolytic anemia Abcuro announced topline results from its Phase 2/3 study of ulviprubart in patients with inclusion body myositis ( Ref ) Abcuro announced topline results from its Phase 2/3 MUSCLE/ NCT05721573 study, which evaluated ulviprubart (ABC008; anti-KLRG1) for the tre